Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study

Tetsuzo Tauchi, MD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 1582.

https://doi.org/10.1182/blood.V130.Suppl_1.1582.1582

Published: 2017

Journal Articles

Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC)

Tetsuzo Tauchi, MD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2017) 130 (Supplement 1): 1249.

https://doi.org/10.1182/blood.V130.Suppl_1.1249.1249

Published: 2017

Journal Articles

Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in Terminal Differentiation of MDS-Derived Induced Potent Stem Cells (iPSC)

Tetsuzo Tauchi, MDPhD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MDPhD, Kazuma Ohyashiki, MD PhD

Blood (2016) 128 (22): 3150.

https://doi.org/10.1182/blood.V128.22.3150.3150

Published: 2016

Journal Articles

Targeting the Hedgehog Signaling Pathway By PF-04449913 Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC): Molecular Mechanisms

Tetsuzo Tauchi, MDPhD, Seiichi Okabe, MD PhD, Seiichiro Katagiri, MD, Yuko Tanaka, MDPhD, Kaoru Tohyama, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2015) 126 (23): 791.

https://doi.org/10.1182/blood.V126.23.791.791

Published: 2015

Journal Articles

Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells

Seiichi Okabe, MD PhD, Tetsuzo Tauchi, MD PhD, Yuko Tanaka, MDPhD, Seiichiro Katagiri, MD PhD, Kazuma Ohyashiki

Blood (2014) 124 (21): 3127.

https://doi.org/10.1182/blood.V124.21.3127.3127

Published: 2014

Journal Articles

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Seiichiro Katagiri, MD PhD, Tetsuzo Tauchi, MD PhD, Yuu Saito, MD, Tamiko Sugro, MD, Michiyo Asano, MD, Seiichiro Yoshizawa, MD PhD, Juri Sakuta, MD PhD, Daigo Akahane, MD PhD, Yuko Tanaka, MD PhD, Nahoko Furuya, MD PhD, Keiko Ando, MD PhD, Hiroaki Fujimoto, MD, Seiichi Okabe, MD PhD, Moritaka Gotoh, MD PhD, Yoshikazu Ito, MD PhD, Tomohiro Umezu, PhD, Junko H Ohyashiki, MD PhD, Kazuma Ohyashiki, MD PhD

Blood (2014) 124 (21): 1797.

https://doi.org/10.1182/blood.V124.21.1797.1797

Published: 2014

Journal Articles

Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, MD PhD, Seiichiro Katagiri, MD, Seiichi Okabe, MD PhD, Yuko Tanaka, MDPhD, Kazuma Ohyashiki, MD, PhD

Blood (2014) 124 (21): 905.

https://doi.org/10.1182/blood.V124.21.905.905

Published: 2014

Journal Articles

High Frequencies Of Switching To 2 nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants

Seiichiro Katagiri, MD, Tetsuzo Tauchi, MD, Tomohiro Umezu, PhD, Kazuhiro Ohtsuki, PhD, Kenichi Tadokoro, Yoshinori Yamamoto, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 4021.

https://doi.org/10.1182/blood.V122.21.4021.4021

Published: 2013

Journal Articles

Activity Of Omacetaxine Mepesuccinate Against Ponatinib Resistant Philadelphia Chromosome Positive Leukemia Cells

Seiichi Okabe, MD, Tetsuzo Tauchi, MD, Yuko Tanaka, MD, Seiichiro Katagiri, MD, Toshihiko Kitahara, MD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 3840.

https://doi.org/10.1182/blood.V122.21.3840.3840

Published: 2013

Journal Articles

Targeting The Dopamine Receptor Signaling Limits The Self-Renewal Of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Tetsuzo Tauchi, MD, Seiichiro Katagiri, MD, Seiichi Okabe, M.D., Yosuke Minami, MD, PhD, Tomoki Naoe, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2013) 122 (21): 1298.

https://doi.org/10.1182/blood.V122.21.1298.1298

Published: 2013

Journal Articles

Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Seiichiro Katagiri, MD, Yuko Tanaka, MD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 1333.

https://doi.org/10.1182/blood.V120.21.1333.1333

Published: 2012

Journal Articles

Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells

Seiichi Okabe, M.D., Tetsuzo Tauchi, M.D., Seiichiro Katagiri, MD, Yuko Tanaka, MD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 3737.

https://doi.org/10.1182/blood.V120.21.3737.3737

Published: 2012

Journal Articles

Activation Levels of Natural Killer Cells and CD8 + T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients

Seiichiro Katagiri, MD, Izuru Mizoguchi, PhD, Takayuki Yoshimoto, PhD, Junichiro Mizuguchi, MD, PhD, Junko H Ohyashiki, MD, PhD, Kazuma Ohyashiki, MD, PhD

Blood (2012) 120 (21): 3745.

https://doi.org/10.1182/blood.V120.21.3745.3745

Published: 2012

NARROW

ABL001 with Catalytic-Site Inhibitors Limit the CML Immature Cell Population: Re-Differentiation of CML-iPSCs Study

Combining Effects of the SMO Inhibitor and BCL-2 Inhibitor in MDS-Derived Induced Potent Stem Cells (iPSC)

Combining Effects of the SMO Inhibitor and Jak1 Inhibitor in Terminal Differentiation of MDS-Derived Induced Potent Stem Cells (iPSC)

Targeting the Hedgehog Signaling Pathway By PF-04449913 Limits the Self-Renewal of MDS-Derived Induced Potent Stem Cells (iPSC): Molecular Mechanisms

Anti-Leukemic Activity of Phosphoinositide 3-Kinase Inhibitor, Copanlisib in ABL Tyrosine Kinase Resistant Leukemia Cells

BCL2L11 ( BIM ) Deletion Polymorphism Is Associated with Molecular Relapse after ABL Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia with Complete Molecular Response

Activity of the Stemness Inhibitor, BBI608, on the Self-Renewal of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

High Frequencies Of Switching To 2 nd TKIs and Failure To Maintain Standard Imatinib Dose In Japanese CML Patients With BIM Genetic Variants

Activity Of Omacetaxine Mepesuccinate Against Ponatinib Resistant Philadelphia Chromosome Positive Leukemia Cells

Targeting The Dopamine Receptor Signaling Limits The Self-Renewal Of BCR-ABL1 Positive Leukemia Cells: Molecular Mechanisms

Activity of the Aurora Kinase Inhibitor, MLN8237 (alisertib) Alone or in Combination with Ponatinib Against Imatinib-Resistant BCR-ABL-Positive Cells

Combining ABL1 Kinase Inhibitor, Imatinib and the Jak Kinase Inhibitor TG101348: A Potential Treatment for Residual BCR-ABL Positive Leukemia Cells

Activation Levels of Natural Killer Cells and CD8 + T Cells Correlate Highly with Sustained Complete Molecular Response After Discontinuation of Imatinib in Chronic Myeloid Leukemia Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only